13.05.2021 | ASO Research Letter
Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer
verfasst von:
Alexander J. Rossi, MD, Tahsin M. Khan, MD, Hanna Hong, BS, Gregory B. Lesinski, Phd, MPH, Christina Wu, MD, Jonathan M. Hernandez, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Excerpt
Semaphorin 4D (SEMA4D) is a transmembrane protein that in combination with its main receptor, PlexinB1, plays an important role in tumor invasion and angiogenesis by regulating multiple cell types within the tumor microenvironment (TME), including immune cells, endothelial cells, and cancer cells.
1 In colorectal cancer (CRC), SEMA4D overexpression is reported to be a prognostic indicator and has been found to correlate with histologic tumor type, tumor-node-metastasis (TNM) stage, and lymphatic spread.
2 It also has been identified as a potential target for anti-angiogenic therapy for CRC because SEMA4D is associated with increased tumor angiogenesis.
3 …